Profile data is unavailable for this security.
About the company
QuiaPEG Pharmaceuticals Holding AB is a Sweden-based biotechnology company. The Company develops improved versions of clinically validated biopharmaceutical drugs based on PEGylation technology platform. The Company’s technology is applicable on proteins, peptides and small molecules and offers a half-life extension platform consisting of covalent, as well as extended release PEGylation. The Company focuses on development of long-acting biopharmaceuticals for the treatment of metabolic disorders. The main project intends to reduce the frequent injection therapy by requiring significantly fewer injections. The Company offers out-licensing and partnering opportunities. It has a patent portfolio with patents pending and an approved the United States patent covering chemical linkers.
- Revenue in SEK (TTM)0.00
- Net income in SEK-16.52m
- Incorporated2004
- Employees8.00
- LocationQuiaPEG Pharmaceuticals Holding ABUppsala Business ParkVirdings Alle 32 BUPPSALA 754 50SwedenSWE
- Phone+46 87780006
- Fax+46 87780005
- Websitehttps://www.quiapeg.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XP Chemistries AB | 663.69k | -8.04m | 4.67m | 2.00 | -- | 0.1818 | -- | 7.04 | -0.2846 | -0.2846 | 0.0213 | 0.275 | 0.023 | 0.2084 | 5.99 | 331,845.00 | -27.79 | -- | -29.36 | -- | 50.57 | -- | -1,211.24 | -- | 5.79 | -- | 0.00 | -- | -37.14 | -- | -1.55 | -- | -- | -- |
| Eurocine Vaccines AB | 5.00k | -15.06m | 4.99m | 3.00 | -- | -- | -- | 997.93 | -0.1472 | -0.1472 | 0.00005 | -0.0018 | 0.0007 | -- | 0.002 | -- | -199.76 | -83.17 | -323.19 | -97.89 | -199,780.00 | -- | -301,180.00 | -- | -- | -- | -- | -- | -- | -- | 8.95 | -- | -- | -- |
| European Institute of Science AB | 600.00k | -2.72m | 5.77m | 0.00 | -- | 1.43 | -- | 9.62 | -4.25 | -4.25 | 0.9397 | 2.98 | 0.1728 | 0.8479 | 8.63 | -- | -78.21 | -93.04 | -82.77 | -103.14 | 62.33 | 67.01 | -452.67 | -518.82 | 10.54 | -- | -- | -- | 13.69 | 8.54 | 0.4062 | -- | -- | -- |
| QuiaPEG Pharmaceuticals Holding AB | 0.00 | -16.52m | 5.96m | 8.00 | -- | 0.3908 | -- | -- | -3.51 | -3.51 | 0.00 | 0.2047 | 0.00 | -- | -- | -- | -50.53 | -95.67 | -100.54 | -207.86 | -- | 262.59 | -- | -5,002.50 | -- | -15.34 | 0.00 | -- | -- | -- | 17.75 | -- | 47.06 | -- |
| Bio Vitos Pharma AB | 2.98m | -12.87m | 6.13m | 1.00 | -- | 1.59 | 11.95 | 2.06 | -0.2547 | -0.2547 | 0.0533 | 0.1119 | 0.0989 | 0.00 | 5.38 | 2,983,990.00 | -42.63 | -31.11 | -44.50 | -32.92 | 100.00 | -- | -431.21 | -1,026.76 | 4.27 | -- | 0.00 | -- | 126.97 | -- | 13.64 | -- | -- | -- |
| Lipidor AB | 77.00k | -11.49m | 6.69m | -- | -- | -- | -- | 86.93 | -0.3964 | -0.3964 | 0.0027 | -0.3223 | 0.0084 | -- | 5.31 | -- | -124.54 | -59.41 | -- | -75.10 | -- | -- | -14,916.88 | -643.36 | -- | -- | -- | -- | 73.33 | -20.33 | 72.24 | -- | -- | -- |
| 2cureX AB | 155.00k | -30.82m | 7.11m | -- | -- | 0.5195 | -- | 45.88 | -1.75 | -1.75 | 0.0088 | 0.7777 | 0.0048 | -- | 0.0838 | -- | -95.89 | -38.21 | -108.66 | -43.48 | -6,889.68 | -22,153.06 | -19,883.23 | -38,685.30 | -- | -46.08 | -- | -- | 72.22 | -- | -3.52 | -- | -- | -- |
| Stayble Therapeutics AB | 0.00 | -23.74m | 9.83m | 3.00 | -- | 0.5957 | -- | -- | -0.9492 | -0.9492 | 0.00 | 0.5204 | 0.00 | -- | -- | 0.00 | -116.21 | -78.64 | -141.76 | -95.58 | -- | -- | -- | -- | -- | -- | 0.049 | -- | -- | -- | 3.22 | -- | -- | -- |
| Amniotics AB (publ) | 0.00 | -30.87m | 10.66m | 6.00 | -- | 0.6803 | -- | -- | -0.0374 | -0.0374 | 0.00 | 0.0057 | 0.00 | -- | -- | 0.00 | -112.25 | -101.09 | -362.71 | -149.92 | -- | -- | -- | -- | 1.12 | -16.17 | -- | -- | -- | -- | 35.75 | -- | -- | -- |
| Carbiotix AB (publ) | 1.47m | -13.48m | 13.19m | 10.00 | -- | 0.1918 | -- | 9.00 | -0.302 | -0.302 | 0.0324 | 0.3817 | 0.0586 | -- | 2.36 | 146,552.00 | -53.88 | -49.38 | -64.85 | -55.50 | 235.45 | 574.69 | -919.76 | -1,828.86 | -- | -76.28 | 0.1384 | -- | 259.56 | -12.04 | -10.02 | -- | 13.64 | -- |
| Aptahem AB | 32.00k | -11.11m | 14.18m | -- | -- | 0.1386 | -- | 443.00 | -0.0497 | -0.0497 | 0.0001 | 0.2266 | 0.0005 | -- | 0.0738 | -- | -16.76 | -39.26 | -19.47 | -44.19 | 4,623.59 | -- | -34,727.72 | -- | -- | -10.17 | 0.0847 | -- | -- | -- | -25.36 | -- | -- | -- |
| AegirBio AB | 99.00k | -367.00m | 14.84m | 1.00 | -- | 1.66 | -- | 149.86 | -24.31 | -24.31 | 0.0047 | 0.2895 | 0.0004 | 2.00 | 0.0207 | -- | -163.02 | -- | -171.79 | -- | -24,398.99 | -- | -370,710.10 | -- | 2.53 | -27.27 | 0.8209 | -- | -87.16 | -- | -292.98 | -- | -- | -- |
Data as of May 06 2024. Currency figures normalised to QuiaPEG Pharmaceuticals Holding AB's reporting currency: Swedish Krona SEK
